GlassScriptPhysician profile
Elizabeth Ward
NPI 1891926754
$5,511.69
in general payments reported to CMS, 2019-2025
23 companies · $1,744 in 2025
The $1,744 reported for 2025 was more than what 94% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $788 · 2022: $987 · 2023: $442 · 2024: $1,550 · 2025: $1,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,736.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,895.95 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $587.02 | 2021-2025 | Farxiga, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $548.93 | 2021-2024 | Jardiance |
| Boston Scientific Corporation | $501.57 | 2022-2025 | Watchman Access System |
| Medtronic, INC. | $334.38 | 2022-2025 | Aurora Ev-Icd Mri Surescan, Symplicity G3 |
| E.R. Squibb & Sons, L.L.C. | $329.78 | 2021-2025 | Camzyos, Eliquis |
| Inspire Medical Systems, INC. | $251.28 | 2024-2025 | Inspire |
| Merck Sharp & Dohme LLC | $204.05 | 2021-2025 | Verquvo |
| Pfizer INC. | $125.41 | 2021-2025 | |
| Amgen INC. | $117.94 | 2021-2025 | Repatha |
| Alnylam Pharmaceuticals INC. | $87.57 | 2025 | Amvuttra |
| Lilly USA, LLC | $75.01 | 2025 | Zepbound |
| Lexicon Pharmaceuticals, INC. | $66.60 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $60.09 | 2023-2025 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $59.54 | 2024 | Arcalyst |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $57.24 | 2022-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $46.35 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $44.27 | 2021-2025 | Lifevest |
| Bridgebio Pharma, INC. | $42.25 | 2025 | Attruby |
| Scpharmaceuticals INC. | $29.56 | 2023-2024 | |
| Glaxosmithkline, LLC. | $17.43 | 2025 | Shingrix, Arexvy |
| Shield Therapeutics INC | $15.59 | 2023 | Accrufer |
| Esperion Therapeutics, INC. | $13.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.